Sun Pharmaceutical Industries, Inc.
PharmaMumbai, India, India · Est. 1983 · 24,000 employees
Sun Pharmaceutical Industries is a global pharmaceutical company focused on generic medicines, specialty pharmaceuticals, and branded products across multiple therapeutic areas.
2
Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
1
Indications↗
Distinct diseases across all programs
79
Clinical Trials↗
All sponsored trials (all statuses)
48
Orange Book Patents
Across 7 drugs with upcoming expirations
Pipeline
Pipeline Snapshot
By Phase
2 drugs in development
Phase 32
By Therapeutic Area
top 1
Immunology
2100%
R&D Momentum
27/100
Pipeline Velocity
15/100
Trial Completion Rate
93/100
Pipeline Concentration
100/100
Pipeline Freshness
74/100
Activity
Key Events
Sep 1, 2026TrialA Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group Study Comparing Ivermectin Cream 1% (Taro Pharmaceutical Industries, Inc.) To Soolantra™ Cream 1% (US Reference Listed Drug), PrRosiver® Cream 1% (Canadian Reference Product), and Each Active Treatments to a Placebo Control in the Treatment of Moderate to Severe Facial Rosacea.
Aug 26, 2026FDALupron — VOBRIG
Jul 16, 2026FDAIlumya — ILUMYA
Dec 12, 2025FDAIlumya — ILUMYA
Nov 29, 2025TrialStudy of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Upper Extremities
Nov 19, 2025TrialStudy of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Face and Scalp
Aug 25, 2025FDALupron — CAMCEVI ETM
Aug 5, 2025TrialStudy to Evaluate the Efficacy and Safety of Deuruxolitinib in Adolescents With Severe Alopecia Areata
Details
Company Info
Company Overview
$9.5B
Mkt Cap
$4.8B
Revenue
—
Cash
CEODilip Shanghvi
Founded1983
Employees24,000
HQMumbai, India, India
Websitesunpharma.com
LinkedInCompany Page
Therapeutic Focus
Specialty pharmaceuticalsgeneric drugsophthalmologydermatology
Pipeline
Drug Pipeline
Indication
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Immunology
Immunology
Regulatory
Regulatory Timeline
20171 event
FDAJun 6
Levulan — GLEOLAN
Application NDA208630 (NDA)
20185 events
FDANov 6
Lexette — BRYHALI
Application NDA209355 (NDA)
FDAAug 28
Lupron — LEUPROLIDE ACETATE FOR DEPOT SUSPENSION
Application NDA205054 (NDA)
FDAMay 24
Lexette — LEXETTE
Application NDA210566 (NDA)
FDAMar 20
Ilumya — ILUMYA
Application BLA761067 (BLA)
FDAMar 20
Ilumya — ILUMYA
Application BLA761067
20203 events
FDAAug 26
Winlevi — WINLEVI
Application NDA213433 (NDA)
FDAJun 26
Sandostatin — MYCAPSSA
Application NDA208232 (NDA)
FDAMay 1
Lupron — FENSOLVI KIT
Application NDA213150 (NDA)
20211 event
FDAMay 25
Lupron — CAMCEVI KIT
Application NDA211488 (NDA)
20222 events
FDADec 19
Ilumya — ILUMYA
Application BLA761067
FDANov 17
Luminal — SEZABY
Application NDA215910 (NDA)
20244 events
FDADec 13
UNLOXCYT — UNLOXCYT
Application BLA761297 (BLA)
FDASep 27
Sandostatin — BYNFEZIA PEN
Application NDA213224 (NDA)
FDAJul 25
Leqselvi — LEQSELVI
Application NDA217900 (NDA)
FDAApr 3
Ilumya — ILUMYA
Application BLA761067
20252 events
FDADec 12
Ilumya — ILUMYA
Application BLA761067
FDAAug 25
Lupron — CAMCEVI ETM
Application NDA219745 (NDA)
20262 events
FDAAug 26
Lupron — VOBRIG
Application NDA213225 (NDA)
FDAJul 16
Ilumya — ILUMYA
Application BLA761067
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)